A61K 45 - Medicinal preparations containing active ingredients not provided for in groups

Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
12/2006
12/13/2006	EP1731169A1 Remedies for prostatic hypertrophy
12/13/2006	EP1731167A1 Vaccine against hbv and hpv
12/13/2006	EP1731162A2 Apparatus, method and compositions for the treatment of cancers by ultraphoresis
12/13/2006	EP1731160A1 Cancer metastasis inhibitory composition
12/13/2006	EP1731155A2 Beta-D-2', 3' -Didehydro-2',3' -Dideoxy-5-Fluorocydine for use in the treatment of HIV infections
12/13/2006	EP1731150A1 Niosome having metal porphyrin complex embedded therein, process for producing the same and drug with the use thereof
12/13/2006	EP1731139A1 S/o type pharmaceutical preparation and process for producing the same
12/13/2006	EP1730260A2 Regulatory t cells and their use in immunotherapy and suppression of autoimmune responses
12/13/2006	EP1729809A2 Dietary supplement and method for treating digestive system-related disorders
12/13/2006	EP1729808A2 Combination therapy with azd2171 and 5-fu and/or cpt-11
12/13/2006	EP1729807A2 Combination therapy
12/13/2006	EP1729767A1 Combination of a heterocyclic compound and an antioxidant and use thereof for treating obesity
12/13/2006	EP1729764A2 Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
12/13/2006	EP1729762A2 Combination therapy for weight management
12/13/2006	EP1729761A1 Cadasil treatment with cholinesterase inhibitors
12/13/2006	EP1729749A2 Use of renin inhibitors in therapy
12/13/2006	EP1482975B1 Prevention of tissue adhesion
12/13/2006	EP1478372B1 Long acting parasiticidal composition containing a salicylanilide compound, a polymeric species and at least one other anti-parasitic compound
12/13/2006	EP1425014B1 Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as ppar activators
12/13/2006	EP1392676B1 Heterocyclic urea derivatives and their use as dopamine d3 receptor ligands
12/13/2006	EP1372737B8 Preparation for the prophylaxis of restenosis
12/13/2006	EP1313488B1 Compositions and methods for improving cardiovascular function
12/13/2006	EP1289487B1 Pre-formed sheet devices suitable for topical application
12/13/2006	EP1272219B1 New combination of a betablocker and a cholesterol-lowering agent
12/13/2006	EP1197143B1 Goodpasture's syndrome model mouse
12/13/2006	EP1179067B1 Neuroprotective properties of gdf-15, a member of the tgf-beta superfamily
12/13/2006	EP1171156B1 Isolierte inslen, die insulin-produzierende zellen enthalten, beschichtete mit heparin
12/13/2006	EP1148880B1 Methods for restoring and/or enhancing accommodation in pseudo phakia
12/13/2006	EP1143989B1 Exendins for glucagon suppression
12/13/2006	EP1143896B1 Methods of hydrating the nasal mucosal surface
12/13/2006	EP1024836B1 Compositions for delivering genes to antigen presenting cells of the skin
12/13/2006	CN1878569A Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
12/13/2006	CN1878558A Graduated estrogen contraceptive
12/13/2006	CN1878555A Combination comprising n-(3-methoxy-5-methylpyrazin-2yl)-2-(4-[1,3,4-oxadiazol-2-y1]pyridine-3-sulphonamide and an lhrh analogue and/or bisphosphonate
12/13/2006	CN1878548A Combinations of at1-antagonists, amiloride or triamterine, and a diuretic.
12/13/2006	CN1878546A Combination comprising an alpha-2-delta ligand and an SSRI and/or SNRI for treatment of depression and anxiety disorders
12/13/2006	CN1878545A Thyroid hormone analogs and methods of use
12/13/2006	CN1878536A Antimicrobial compositions and methods
12/13/2006	CN1878529A Combined cosmetic or therapeutic preparation
12/13/2006	CN1878464A Therapeutic delivery of carbon monoxide
12/13/2006	CN1876184A Formulation for treating disease infected by helicobacter pylori
12/13/2006	CN1876183A Methods and compositions for augmenting cancer chemotherapeutic agents
12/13/2006	CN1876182A Ultraviolet resistant formulation obtained from cell engineering technology
12/13/2006	CN1875966A Pharmaceutical combinations and their use in treating gastrointestinal disorders
12/13/2006	CN1875940A Anticancer sustained release agent containing clorfarabine and its synergist
12/13/2006	CN1875939A A sustained release anticancer agent carrying angiogenesis inhibitor and clorfarabine
12/13/2006	CN1875938A A sustained release anticancer injection containing clorfarabine and its synergist
12/13/2006	CN1875936A Anticancer sustained release agent containing clorfarabine and cytotoxic drug
12/13/2006	CN1875935A A sustained release anticancer agent containing clorfarabine and cytotoxic drug
12/13/2006	CN1875934A An anticancer sustained release injection carrying clorfarabine and its synergist
12/13/2006	CN1875933A Sustained release anticancer agent carrying angiogenesis inhibitor and cytotoxic drug
12/13/2006	CN1875932A A compound sustained release anticancer agent containing angiogenesis inhibitor
12/13/2006	CN1875931A An anticancer sustained release agent carrying angiogenesis inhibitor and cytotoxic drug
12/13/2006	CN1875930A An anticancer sustained release injection carrying tumor drug resistance reversal agent and cytotoxic drug simultaneously
12/13/2006	CN1875929A An anticancer sustained release injection carrying tumor drug resistance reversal agent and reversal agent synergist
12/13/2006	CN1875928A Anticancer sustained release injection containing tumor drug resistance reversal agent and cytotoxic drug
12/13/2006	CN1289490C Oxa-and thiazole derivatives useful as antidiabetic and antibesity agents
12/13/2006	CN1289471C 3,4-di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
12/13/2006	CN1289142C Medicinal new dosage form containing SA liposome as medicine carrier
12/13/2006	CN1289090C Highly selective norepinephrine reuptake inhibitors and use thereof in medicament preparation
12/13/2006	CN1289087C Quinoline derivatives as neuropeptide y antagonists
12/13/2006	CN1289084C Pharmaceutical formulation
12/13/2006	CN1289082C Medicine composition for treating diabetes
12/13/2006	CN1289081C Pharmaceutical composition for modified release insulin sensitiser
12/13/2006	CN1289064C Drug delivery system
12/13/2006	CN1289059C Pre-formed sheet devices suitable for topical application
12/12/2006	US7148333 Stabilization; administering by injection
12/12/2006	US7148331 Isolated human dehydrogenases, nucleic acid molecules encoding these human dehydrogenases, and uses thereof
12/12/2006	US7148329 For modulating, in particular increasing or reducing, the immune response in an animal, such as a human or another mammal
12/12/2006	US7148237 Nitrogen-containing heteroaryl compounds having HIV integrase inhibitory activity
12/12/2006	US7148234 Use of EP4 receptor ligands in the treatment of IL-6 involved diseases
12/12/2006	US7148233 Treatment of cardiovascular and related pathologies
12/12/2006	US7148216 Combinations of drugs for the treatment of neoplastic disorders
12/12/2006	US7148215 Prodrugs as antihistamines or anticarcinogenic agents
12/12/2006	US7148190 Haptotactic peprides
12/12/2006	US7148038 Immunotherapy; antiproliferative agent
12/12/2006	US7148006 Screenining and detection of antiproliferative agentst; obtain tumor cells, incubate with antiproliferative agents, monitor reduction in tumor activity
12/12/2006	US7148002 Nucleic acids and polypeptides related to a guanine exchange factor of Rho GTPase
12/12/2006	US7147869 Rapidly disintegrating tablet comprising an acid-labile active ingredient
12/12/2006	US7147862 Vaccines containing QS21, an Hplc purified non-toxic fraction derived from the bark of Quillaja Saponaria Molina, and 3 De-O-acylated monophosphoryl lipid A (3 D-MPL); combinations of QS21 and 3 D-MPL synergistically enhance immune responses to a given antigen
12/12/2006	US7147471 Use of moulding compounds for producing treatment devices
12/12/2006	CA2347741C Thiazole-derivatives
12/12/2006	CA2305394C Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
12/12/2006	CA2286076C Use of 5ht3 antagonists for promoting intestinal lavage
12/12/2006	CA2215680C Prilocaine and hydrofluorocarbon aerosol preparations
12/12/2006	CA2179294C Low molecular weight hyaluronic acid with peptide or protein
12/12/2006	CA2159355C Method and composition for treatment of osteoporosis
12/12/2006	CA2098176C Angiotensin ii receptor blocking compositions
12/07/2006	WO2006130627A2 Methods for treating hepatitis c
12/07/2006	WO2006130187A1 Feline probiotic lactobacilli
12/07/2006	WO2006129881A1 Prophylactic/therapeutic agent for bone/joint disease and screening method for the agent
12/07/2006	WO2006129877A1 Novel anti-inflammatory agent
12/07/2006	WO2006129859A2 Combinations of a squalene synthase inhibitor and a hmg-coa reductase inhibitor for treating hyperlipidemia
12/07/2006	WO2006129842A1 Novel aminopyridine derivative having selective aurora-a inhibitory activity
12/07/2006	WO2006129788A1 Agent for regeneration and/or protection of nerves
12/07/2006	WO2006129785A1 Concomitant pharmaceutical agents and use thereof
12/07/2006	WO2006129784A1 INTERFERON-α REGULATOR
12/07/2006	WO2006129193A2 Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
12/07/2006	WO2006128847A2 Medicament containing a betamimetic in conjunction with an anticholinergic and a pde iv inhibitor
12/07/2006	WO2006128675A1 Indacterol derivatives and phosphodiesterase inhibitors for the treatment of airway diseases

1 ... 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 ... 1151